(Q36821503)

16 August 2017

1 reference

title

Outcome measures in systemic sclerosis: an update on instruments and current research (English)

1 reference

16 August 2017

Dinesh Khanna

1

1 reference

16 August 2017

Peter A Merkel

series ordinal

2

1 reference

16 August 2017

publication date

1 May 2007

1 reference

Current Rheumatology Reports

16 August 2017

published in

1 reference

16 August 2017

volume

9

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

151-157

1 reference

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11926-007-0010-5

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-007-0010-5

Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-007-0010-5

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-007-0010-5

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-007-0010-5

Scleroderma--developing measures of response

21 January 2018

1 reference

12 December 2020

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

1 reference

12 December 2020

Health values of patients with systemic sclerosis.

1 reference

12 December 2020

Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument

1 reference

12 December 2020

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

12 December 2020

Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis

1 reference

12 December 2020

Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis.

1 reference

12 December 2020

Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial

1 reference

12 December 2020

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

1 reference

12 December 2020

Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis

1 reference

12 December 2020

The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time

1 reference

12 December 2020

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

1 reference

12 December 2020

The OMERACT filter for Outcome Measures in Rheumatology

1 reference

12 December 2020

Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis

1 reference

12 December 2020

Seventeen-point dermal ultrasound scoring system--a reliable measure of skin thickness in patients with systemic sclerosis

1 reference

12 December 2020

Predictors of survival in systemic sclerosis (scleroderma)

1 reference

12 December 2020

Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.

1 reference

12 December 2020

Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis

1 reference

12 December 2020

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy

1 reference

12 December 2020

Durometry for the assessment of skin disease in systemic sclerosis.

1 reference

12 December 2020

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study

1 reference

12 December 2020

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

1 reference

12 December 2020

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

1 reference

12 December 2020

Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients

1 reference

12 December 2020

Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

1 reference

12 December 2020

Gastrointestinal features of scleroderma

1 reference

12 December 2020

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

1 reference

12 December 2020

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes

1 reference

12 December 2020

Effect of H2-receptor antagonists cimetidine and famotidine on interdigestive gastric motor activity and lower esophageal sphincter pressure in progressive systemic sclerosis

1 reference

12 December 2020

Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.

1 reference

12 December 2020

Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis

1 reference

12 December 2020

Severe restrictive lung disease in systemic sclerosis.

1 reference

12 December 2020

Autoantibodies in systemic sclerosis

1 reference

12 December 2020

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

12 December 2020

Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis

1 reference

12 December 2020

Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

12 December 2020

Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension

1 reference

12 December 2020

Accuracy of high resolution CT in assessing idiopathic pulmonary fibrosis histology by objective morphometric index.

1 reference

12 December 2020

Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial

1 reference

12 December 2020

CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.

1 reference

12 December 2020

Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test

1 reference

12 December 2020

Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial

1 reference

12 December 2020

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

12 December 2020

10.1007/S11926-007-0010-5

Identifiers

DOI

1 reference

16 August 2017

1 reference